MET and Parkinson disease: In our study, MPP+-treated SH-SY5Y neuronal cells were used as a PD model to evaluate the effects of MET and RAPA combinations on cell viability and an autophagy marker, LC3-II, including the autophagy-related Akt/S6K1 pathway.